<DOC>
	<DOCNO>NCT00984919</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood urine patient cancer laboratory may help doctor identify biomarkers related cancer . PURPOSE : This research study look biomarker , 11-dh-TXB2 , blood urine sample patient prostate cancer healthy volunteer .</brief_summary>
	<brief_title>Biomarker 11-dh-TXB2 Blood Urine Samples From Patients With Prostate Cancer Healthy Volunteers</brief_title>
	<detailed_description>OBJECTIVES : - To identify potential novel marker prostate cancer blood urine , 11-dh-TXB2 , use screen tool prostate cancer well detection early relapse patient previously treat early-stage prostate cancer . OUTLINE : Blood urine sample collect analyzed plasma urinary 11-dh-TXB2 level HPLC tandem-mass spectrometry .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Meets one follow criterion : Histopathologically confirm prostate cancer meet 1 follow criterion : Newly diagnose untreated disease Received prior local therapy ( prostatectomy , definitive radiotherapy , brachytherapy , cryotherapy ) evidence disease activity ( define serum PSA &lt; 0.4 ng/mL post therapy ) image study Experienced biochemical failure ( define rise serum PSA â‰¥ 0.4 ng/mL post therapy ) Healthy volunteer ( clinic patient history clinically significant malignancy within past 6 month ) PATIENT CHARACTERISTICS : No clinical evidence liver cirrhosis chronic liver disease ( i.e. , evidence ascites severe coagulopathy ) No active prostatitis PRIOR CONCURRENT THERAPY : See Disease Characteristics More 30 day since prior concurrent regular antiplatelet agent ( include aspirin , anagrelide , cilastazole , clopidogrel , dipyridamole , pentoxiphylline , sulfinpyrazone , ticlopidine ) More 7 day since prior concurrent NSAIDs ( include ibuprofen , celecoxib , diclofenac , diflunisal , etodolac , fenoprofen , flurbiprofen , indomethacin , ketoprofen , meclofenamate , mefenamic acid , nabumetone , naproxen , oxaprozin , piroxicam , sulindac , tolmetin )</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>